GNPH - Genesis Pharmaceuticals Enterprises
Sehr schön...sollten wir nochmals unter 6 dollar fallen leg ich noch ein paar nach.
Angehängte Grafik:
gnph.gif
gnph.gif
Viele Shares in festen Händen,wenn da jemand rein will,gehts hoch.
Es kann ja auch das Aktienrückkaufpacket sein?
Auf steigende Kurse,erstes Ziel:10USD
Mehr gabs ned..:-( , naja ich hab ja eh schon genug hehe..
Stuttgart jetzt 1000 für 6.05€ hahahahahankfurt 5.50€ 0 Stück...hehehe
Find ich gut....lala ;-)
Xetra Leitbörse, Teilausführungen möglich n.a. 0
Stück keine 2,70 EUR
09.12.08 13:57
Frankfurt mehr 5,42 EUR 0
Stück 2,50 € + Courtage 5,40 (G) EUR
21.04.09 09:08
Stuttgart mehr n.a. 0
Stück 2,50 € + Börsenentgelt 4,90 (G) EUR
21.04.09 09:01
Berlin mehr n.a. 0
Stück 2,50 € + Courtage 5,40 (G) EUR
21.04.09 08:39
Genesis Pharmaceuticals Announces the Launch of Three TCM Products
Wednesday April 22, 2009, 8:00 am EDT
23.04.2009 14:04
Genesis Pharmaceuticals Changes its Name to Jiangbo Pharmaceuticals, Inc. to Reflect its Brand Name
LAIYANG, China, April 23 /PRNewswire-Asia-FirstCall/ -- Genesis Pharmaceuticals Enterprises, (News) Inc. (BULLETIN BOARD: GNPH) (the "Company"), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced that it has changed its name to "Jiangbo Pharmaceuticals, Inc." ("Jiangbo").
The Company received confirmation from the Department of State of the State of Florida that the Certificate of Amendment to the Company's Amended and Restated Articles of Incorporation to effect a change of its name was filed. The Board of Directors of the Company as well as the holders of a majority of the outstanding shares of the Company's voting stock approved the name change by written consent. The Company will soon receive a new CUSIP number for its common stock, after which a new ticker symbol for the Company's shares will be assigned by the OTCBB. The Company will announce its new ticker symbol and CUSIP number as soon as it receives them.
The Company's wholly owned operating subsidiary Laiyang Jiangbo Pharmaceutical Co., Ltd., a PRC company, markets the Company's products throughout China under the brand name "Jiangbo." Part of the Company's branding strategy includes using similar packaging for its products and creating a product line of drugs which are widely known by Jiangbo's brand name and logo.
"We support Jiangbo with the idea that 'We aim high, We aim wide.' It is part of our corporate culture to provide our customers with products that will help them lead happy and healthy lives. We always strive to produce the best possible quality products and ensure our reputation while we continue to grow our Company's revenues, profits and value," said Mr. Wubo Cao, Chief Executive Officer of Jiangbo.
"We changed our corporate name to Jiangbo to align the name of our public company with the name of our products. With this change, we hope that our customers, partners and shareholders will view our products as synonymous with our Company. We want people to think of only 'Jiangbo' as we continue to improve our Company and expand our product line," concluded Mr. Cao.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=37357229
http://www.jiangbopharma.com/...&fir_lineid=79&sec_lineid=490
...
OTCBB-listed Jiangbo Pharma is also currently preparing to list on the Nasdaq within the next six to 12 months, Sung said.
...
Angehängte Grafik:
elsa_sung_jiangbo_-_med.jpg
elsa_sung_jiangbo_-_med.jpg
GNPH !!!!!! / Jiangbo Pharmaceuticals Announces New Ticker (JGBO) and CUSIP
Date : 05/11/2009 @ 2:27PM
Source : PR Newswire
Stock : (GNPH)
Quote : 7.5 0.25 (3.45%) @ 4:00PM
Jiangbo Pharmaceuticals Announces New Ticker (JGBO) and CUSIP
LAIYANG, China, May 11 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc. (OTC:GNPH) (BULLETIN BOARD: GNPH) (the "Company"), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced that its stock will start trading on the Over the Counter Bulletin Board under the new ticker symbol "JGBO" as of May 12, 2009. The Company's shares will cease trading under the ticker symbol "GNPH" at the end of May 11, 2009.
The Company's shares will be identified under a new CUSIP: 47737 R 10 1.
About Jiangbo Pharmaceuticals, Inc.
Jiangbo Pharmaceuticals, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong province. Jiangbo is a major pharmaceutical company in China producing both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. http://www.jiangbopharma.com/
Safe Harbor Statement
Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
For more information, please contact:
Jiangbo Pharmaceuticals, Inc.
Ms. Elsa Sung, CFO Phone: +1-954-727-8435 Email: Web: http://www.jiangbopharma.com/
CCG Investor Relations, Inc.
Mr. Crocker Coulson, President Phone: +1-646-213-1915 Email: Web: http://www.ccgirasia.com/
DATASOURCE: Jiangbo Pharmaceuticals, Inc.
CONTACT: Jiangbo Pharmaceuticals, Inc., Ms. Elsa Sung, CFO,
+1-954-727-8435, or CCG Investor Relations, Inc., Mr.
Crocker Coulson, President, +1-646-213-1915, for
Jiangbo Pharmaceuticals, Inc.
Web site: http://www.jiangbopharma.com/
http://www.ccgirasia.com/
<< Back
...siehe auch Beiträge #162 und folgend...
http://www.finanznachrichten.de/...erse-aenderung-change-isin-029.htm
13.05.2009 15:51
DIVERSE: AENDERUNG / CHANGE: ISIN
FUER FOLGENDE INSTRUMENTE WERDEN ISIN, WKN UND KUERZEL GEAENDERT.
GUELTIG AB: 14.05.2009.
Einstellung Aufnahme
ISIN Kuerzel Name Einst. mit Ablauf: ISIN Kuerzel Name Ab dem:
Anmerkungen
US37184Q2012 (News) GNY1 GENESIS PHARMA.NEW DL-,02 13.05.2009 US47737R1014
GNY1 JIANGBO PHARMAC. DL-,02 14.05.2009 Tausch 1:1
13.05.2009 21:53
Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for its Third Quarter of FY 2009
LAIYANG, China, May 13 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc., (OTC Bulletin Board: JGBO; "Jiangbo" or the "Company") (which recently changed its name from Genesis Pharmaceuticals Enterprises, (News) Inc., OTC Bulletin Board: GNPH), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced that the Company will host a conference call at 9:30 a.m. Eastern on Tuesday, May 19, 2009 to discuss financial results for the third quarter ended March 31, 2009 of its fiscal year 2009.
Conference Call
The conference call will include Mr. Wubo Cao, Chairman and CEO, Mr. Haibo Xu, COO, and Ms. Elsa Sung, CFO, of Jiangbo Pharmaceuticals.
To participate in this live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: (888) 481-7939. International callers should call (617) 847-8707. The Conference Passcode is 564 145 01.
If you are unable to participate in the call at that time, replay of the conference call will be available from Tuesday, May 19, 2009 at 11:30 a.m. Eastern for fourteen days. To access the replay, call (888) 286-8010. International callers should call (617) 801-6888. The Conference Replay Passcode is 547 268 69.
...(weiter siehe LINK)